Last
Update:
March 30, 2018
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
| |
Decreased darunavir concentrations during
once-daily co-administration with maraviroc and raltegravir:
OPTIPRIM-ANRS 147 trial.
Pressiat C, Hirt D, Treluyer JM, Zheng Y,
J Antimicrob Chemother.
2018 Jan
Abstract
Monotherapy with boosted PIs as an ART simplification strategy in
clinical practice.
Santos JR, Llibre JM, Berrio-Galan D,
et al
J Antimicrob Chemother. 2014 Dec
18
Abstract
Efficacy of a reduced dose of Darunavir/RTV in a cohort of
antiretroviral-naïve and experienced HIV-infected patients: a medium-term
follow-up.
Lanzafame M, Lattuada E, Rigo F, Hill A, Vento S
J Int AIDS Soc. 2014 Nov
2;17(4(Suppl 3)):
Abstract
Bioavailability and bioequivalence of a darunavir 800-mg tablet
formulation compared with the 400-mg tablet formulation.
Kakuda TN, Leopold L, Timmers M, et al
Int J Clin Pharmacol Ther. 2014 Sep;52(9):805-16.
Abstract |
| |
|
Durability and tolerability of first-line regimens including two nucleoside
reverse transcriptase inhibitors and raltegravir or ritonavir
boosted-atazanavir or -darunavir: data from the ICONA Cohort.
d'Arminio Monforte A, Lorenzini P, et al
HIV Clin Trials.
2018 Mar 1:1-9.
Abstract
Darunavir/ritonavir monotherapy at a low dose
(600/100 mg/day) in HIV-1-infected individuals with
suppressed HIV viraemia.
Seang S, Schneider L, Nguyen T, Lê MP,
et al
J Antimicrob Chemother.
2017 Dec 5.
Abstract
Multi-spectroscopic and molecular docking
studies on the interaction of darunavir, a HIV protease
inhibitor with calf thymus DNA
Shi JH, Zhou KL, Lou YY, Pan DQ.
Spectrochim Acta A Mol Biomol
Spectrosc.
2017 Nov 29;193
Abstract
Darunavir concentrations in CSF of
HIV-infected individuals when boosted with cobicistat versus
ritonavir.
Bartels H, Decosterd L, Battegay M, Marzolini C.
J Antimicrob Chemother.
2017 Jun 1
Abstract
Plasma trough concentrations of darunavir/ritonavir and
raltegravir in older patients with HIV-1 infection.
Calza L, Colangeli V, Magistrelli E,
et al
HIV Med. 2017 Jan 24.
Abstract
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-,
Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Kelesidis T, Moser C, Stein JH,
J Infect Dis.
2016 Sep 1;214(5):748-52
Abstract
FULL-TEXT
PDF ARTICLE
Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard
antiretroviral therapy: a randomized clinical trial (2pm Study).
Gianotti N, Galli L, Maserati R, Sighinolfi L, et al
New Microbiol. 2016 Aug
23;39(3).
Paper
Long-term clinical experience with darunavir (2007-2015) in a large cohort of
HIV-infected patients in Spain.
Pernas B, Grandal M, Tabernilla A,
et al
J Med Virol.
2016 May 24.
Abstract
Persistence, adherence and all-cause healthcare costs in
atazanavir- and darunavir-treated patients with human immunodeficiency virus in
a real-world setting.
Farr AM, Johnston SS, Ritchings C, et al
J Med Econ. 2015 Dec 7:1-35.
Abstract
Rationale and clinical utility of the darunavir-cobicistat
combination in the treatment of HIV/AIDS.
Putcharoen O, Do T,
Avihingsanon A, Ruxrungtham K.
Drug Des Devel Ther.
2015 Oct 23;9:5763-5769.
Abstract
One-step production of darunavir solid dispersion nanoparticles coated with
enteric polymers using electrospraying.
Nguyen DN, Palangetic L, Clasen C, Van den Mooter G.
J Pharm Pharmacol. 2015
Aug 14.
Abstract
Darunavir and Ritonavir Total and Unbound Plasmatic Concentrations in HIV-HCV
Co-Infected Patients with Hepatic Cirrhosis Compared to HIV Mono-Infected
Patients.
Curran A, Martí R, López RM, Pérez M,
et al
Antimicrob Agents Chemother. 2015
Aug 17.
Abstract
Investigation of Efavirenz Discontinuation in Multi-ethnic
Populations of HIV-positive Individuals by Genetic Analysis.
Cummins NW, Neuhaus J, Chu H, Neaton J, et al
EBioMedicine.
2015 May 12;2(7):706-712.
Abstract
FULL-TEXT ARTICLE
Drug susceptibility to etravirine and darunavir among
Human Immunodeficiency Virus Type 1-derived
pseudoviruses in treatment-experienced patients with
HIV/AIDS in South Korea.
Kwon OK, Kim SS, Rhee JE, et al
Virol J. 2015
Apr 9;12(1):53.
Paper |
Plasma concentrations of efavirenz,
darunavir/ritonavir and raltegravir in
HIV-HCV-coinfected patients without liver cirrhosis
in comparison with HIV-monoinfected patients.
Calza L,
Danese I, Colangeli V, et al
Infect Dis (Lond).
2015 Apr 15:1-12.
Abstract
Plasma concentrations of efavirenz, darunavir/ritonavir and
raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison
with HIV-monoinfected patients.
Calza L, Danese I, Colangeli V, et al
Infect Dis (Lond). 2015 Apr 15:1-12.
Abstract
Antiviral activity and CSF concentrations of 600/100 mg of
darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
Di Yacovo MS, Moltó J, Ferrer E, et al
J Antimicrob Chemother. 2015 Jan 20.
Abstract
Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining
a PI/r-based antiretroviral regimen in persons with suppressed HIV replication.
Pinnetti C, Lorenzini P, Cozzi-Lepri A, et al
J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19809
Abstract
Dimerization of HIV-1 protease occurs through two steps relating
to the mechanism of protease dimerization inhibition by darunavir.
Hayashi H, Takamune N, Nirasawa T, et al
Proc Natl Acad Sci U S A. 2014 Aug 4.
Abstract
Lack of mitochondrial toxicity of darunavir, raltegravir and
rilpivirine in neurons and hepatocytes: a comparison with efavirenz.
Blas-García A, Polo M, Alegre F,
et al
J
Antimicrob Chemother. 2014 Jul 9
Abstract
Evaluation of Atazanavir and Darunavir Interactions with Lipids
for Developing pH-Responsive Anti-HIV Drug Combination Nanoparticles.
Duan J, Freeling JP, Koehn J, et al
J Pharm Sci. 2014 Jun 19.
Abstract
Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding
of Darunavir to Wide Open Flaps.
Zhang Y, Chang YC, Louis JM, et
al
ACS Chem Biol. 2014 Apr 16.
Abstract
Investigation on the mechanism for the binding and drug
resistance of wild type and mutations of G86 residue in HIV-1
protease complexed
with Darunavir by molecular dynamic simulation and free energy calculation.
Li D, Zhang Y, Zhao RN, et
al
J Mol Model. 2014 Feb;20(2):2122.
Abstract
Cellular HIV reservoir replenishment is not affected by
blip or intermittent viremia episodes during darunavir/ritonavir
monotherapy.
Torres-Cornejo A, Benmarzouk-Hidalgo OJ, Gutiérrez-Valencia A, et al
AIDS. 2013 Dec 19
Abstract
Interindividual and Intraindividual Variability's of
Darunavir and Ritonavir Plasma Trough Concentrations in Multidrug
Experienced HIV Patients Receiving Salvage Regimens.
Baroncelli S, Villani P, Galluzzo CM,, et al
Ther Drug Monit. 2013 Sep 20.
Abstract
Determination of P-glycoprotein surface expression and
functional ability after in vitro treatment with darunavir or raltegravir in
lymphocytes of healthy donors.
Tempestilli M, Gentilotti E, Tommasi C, et al
Int Immunopharmacol. 2013 May 23
Abstract
GAM analysis of the relationship between DRV PK and
pharmacodynamics following DRV/r 800/100 mg qd in the phase III trials ARTEMIS
and ODIN.
Kakuda T, Tomaka F, Van De Casteele T, Vangeneugden T.
J Int AIDS Soc. 2012 Nov
11;15(6):18338.
Abstract
No change of plasma darunavir concentrations by switching from
ritonavir soft capsule to tablet.
Shibata M, Takahashi M, Fukushima N,
et al
J Int AIDS Soc. 2012 Nov
11;15(6):18360.
Abstract
Darunavir plasma level in HIV overweight patients.
Poupard M, Boussairi
A, Krause J, Khuong-Josses M.
J Int AIDS Soc. 2012 Nov 11;15(6):18359.
Abstract
Darunavir is predominantly unbound to protein in cerebrospinal
fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory
concentration.
Croteau D, Rossi SS, Best BM,
et
al
J Antimicrob Chemother. 2012 Nov 9
Abstract |
Darunavir: A Critical Review of Its Properties, Use and Drug
Interactions.
Ruela Corrêa JC, D'Arcy DM, Dos Reis Serra CH, et al
Pharmacology. 2012 Jul 12;90(1-2):102
Abstract
Single and Multiple Dose Pharmacokinetics of Darunavir plus Ritonavir and
Etravirine
in Semen and Rectal Tissue of HIV-Negative Men.
Brown KC, Patterson KB, Jennings SH,
J Acquir Immune Defic Syndr.
2012 May 18.
Abstract |
Determinants of darunavir cerebrospinal fluid concentrations: impact of
once-daily dosing and
pharmacogenetics.
Calcagno A, Yilmaz A, Cusato J,
et al
AIDS.
2012 May 2.
Abstract |
Origin of Decrease in Potency of Darunavir and Two Related Antiviral
Inhibitors Against HIV2
Compared to HIV1 Protease.
Kar P, Knecht V
J Phys Chem B.
2012 Jan 26.
Abstract |
Effects of darunavir/ritonavir-based therapy on metabolic and
anthropometric parameters in women and
men over 48 weeks.
Currier JS, Martorell C, Osiyemi O,
et al
AIDS Patient Care STDS.
2011 Jun;25(6):333-40.
Abstract
Positive Impact of HIV-1 Gag Cleavage Site Mutations on Virological
Response to Darunavir
Boosted with Ritonavir.
Larrouy L, Lambert-Niclot S, Charpentier C, Fourati S,
t
al
Antimicrob Agents Chemother.
2011 Jan 31
Abstract
Darunavir concentrations exceed the protein-corrected
EC50 for wild-type HIV in the semen of
HIV-1-infected men.
Taylor S, Jayasuriya AN, Berry A, Gilleran G,
et al
AIDS. 2010
Aug 25
Abstract |
800 mg Darunavir tablets prepared by hot melt
extrusion.
Thommes M, Baert L, Rosier J.
Pharm Dev Technol.
2010 Aug 23.
Abstract |
Low frequency of intermittent HIV-1 semen excretion in patients treated by
darunavir/ritonavir (
600/100 mg BID) + 2 nucleoside reverse transcriptase inhibitors or monotherapy.
Lambert-Niclot S, Peytavin G, Duvivier C, et al
Antimicrob Agents Chemother.
2010 Aug 16
Abstract |
Trends in uptake of recently approved antiretrovirals within a
national healthcare system.
Belperio P, Mole L, Boothroyd D,
Backus L.
HIV Med.
2009 Oct 23.
Abstract |
Intracellular 'boosting' of darunavir using known transport
inhibitors in primary PBMC.
Kwan WS, Janneh O, Hartkoorn R, et al
Br J
Clin Pharmacol. 2009 Sep;68(3):375-80
Abstract |
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics,
and resistance profile
of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA, Robinson L, Tseng A, Macarthur RD.
Expert Opin Pharmacother. 2009
Aug 13.
Abstract |
Identification of new genotypic cut-off levels to predict the efficacy
of lopinavir/ritonavir and
darunavir/ritonavir in the TITAN trial.
Hill A, Marcelin AG, Calvez V.
HIV Med. 2009
Jul 6.
Abstract
|
|
Role of tenofovir in HIV and hepatitis C virus
coinfection.
Tuma P, Vispo E, Barreiro P, Soriano V.
Enferm Infecc Microbiol Clin.
2008 Jun;26(Supl.8):31-37
Abstract
|
TMC114,
a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor
Active
against Protease Inhibitor-Resistant Viruses, Including a Broad
Range of Clinical Isolates.
De Meyer S, Azijn H, Surleraux D, et al
Antimicrob Agents Chemother. 2005 Jun;49(6):2314-21.
Abstract
|
|
| |
Pharmacokinetics of darunavir/cobicistat and etravirine alone
and co-administered in HIV-infected patients.
Moltó J, Curran A, Miranda C, Challenger E, et al
J
Antimicrob Chemother. 2017 Dec
11.
Abstract
Pharmacokinetics of darunavir/cobicistat and etravirine alone and
co-administered in HIV-infected patients.
Moltó J, Curran A, Miranda C, Challenger E, et al
J Antimicrob Chemother.
2017 Dec
Abstract
Physiologically Based Pharmacokinetic Modeling for Predicting the
Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure
Coadministered With Ritonavir.
Wagner C, Zhao P, Arya V,
J Clin Pharmacol. 2017 Jun 1
Abstract
Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both
Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young
Adults.
Cressey TR, Yogev R, Wiznia A,
J Pediatric Infect Dis Soc. 2016 Apr 21
Abstract
Pharmacokinetics and pharmacodynamics of boosted once-daily
darunavir.
Kakuda TN, Brochot A, Tomaka FL,
et al
J Antimicrob Chemother. 2014 Jun 20.
Abstract
Steady-State Pharmacokinetics of
Darunavir/Ritonavir and Pitavastatin when Co-administered to
Healthy Adult Volunteers.
Yu CY, Campbell SE, Sponseller CA,et
al
Clin Drug Investig. 2014
May 14.
Abstract
Population pharmacokinetic modelling and
evaluation of different dosage regimens for darunavir and
ritonavir in HIV-infected individuals.
Arab-Alameddine M, Lubomirov R, Fayet-Mello A, et al
J Antimicrob Chemother.
2014 May 12.
Abstract
Pharmacokinetics of Darunavir in Fixed-Dose Combination with
Cobicistat Compared with Coadministration of Darunavir and
Ritonavir as Single Agents in Healthy Volunteers.
Kakuda TN Opsomer M , Timmers M , et al
J Clin Pharmacol.
2014 Mar 19
Abstract
Simultaneous Pharmacogenetics-Based
Population Pharmacokinetic Analysis of Darunavir and
Ritonavir in HIV-Infected Patients.
Moltó J, Xinarianos G, Miranda C, et al
Clin Pharmacokinet.
2013 Mar 15.
Abstract
Pharmacokinetics of Maraviroc, Raltegravir,
Darunavir, and Etravirine in the Semen of HIV-Infected Men.
Antoniou T, Hasan S, Loutfy MR, et al
J Acquir Immune Defic Syndr.
2013 Feb 1;62(2):e58-60.
Abstract
Pharmacokinetics of Maraviroc, Raltegravir,
Darunavir, and Etravirine in the Semen of HIV-Infected Men.
Antoniou T, Hasan S, Loutfy MR, et al
J Acquir Immune Defic Syndr.
2013 Feb 1;62(2):e58-60.
Abstract |
Simultaneous population pharmacokinetic
modelling of darunavir and ritonavir Once daily in
HIV-infected patients: evaluation of lower ritonavir dose.
Dickinson L, Jackson A, Garvey L,
et
al
J Int AIDS Soc. 2012 Nov
11;15(6):18331
Abstract
Pharmacokinetics of 400 mg of raltegravir
once daily in combination with atazanavir/ritonavir plus two
nucleoside/nucleotide reverse transcriptase inhibitors.
Calcagno A, Tettoni MC, Simiele M,
et sl
J Antimicrob Chemother.
2012 Oct 19.
Abstract |
FULL-TEXT ARTICLE
Pharmacokinetics and Pharmacodynamics of Darunavir and
Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender,
Race, and Clinical Experience (GRACE) Trial.
Kakuda T, Sekar V, Vis P, et al
AIDS Res Treat.
2012;2012:186987
Paper
FULL-TEXT ARTICLE
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in
HIV-1–Infected, Treatment-Experienced Patients
in the Gender, Race, and Clinical
Experience (GRACE) Trial
Kakuda T, Sekar V,
Vis P, et al
AIDS Research and Treatment Vol 2012 Art ID
186987
Paper
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and
raltegravir once and twice daily in
HIV-infected individuals.
Jackson A, Watson V, Back D,
et
al
J Acquir Immune Defic Syndr.
2011 Sep 15.
Abstract
|
Pharmacokinetics of darunavir/ritonavir and atazanavir/ritonavir once daily over
72 hours following drug cessation.
Boffito M, Jackson A, Amara A,
et al
Antimicrob Agents Chemother.
2011 Jun 27
Abstract
Darunavir, Ritonavir and Etravirine Pharmacokinetics in the
Cervicovaginal Fluid and Blood
Plasma of HIV-Infected Women
Patterson K, Jennings S, Falcon R, et al
Antimicrob Agents Chemother.
2010 Dec 20
Abstract
|
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in
treatment experienced
patients.
Barrail-Tran A, Yazdanpanah Y, Goldwirt L, et al
AIDS.
2010 Oct 23;24(16):2581-3.
Abstract
|
Pharmacokinetics of Darunavir/r and Rifabutin Co-administered in
HIV-Negative
Healthy Volunteers.
Sekar V, Lavreys L, Van de Casteele T, et al
Antimicrob Agents Chemother.
2010 Jul 26
Abstract
|
Pharmacokinetics of darunavir at 900 milligrams and
ritonavir at 100 milligrams once daily
when coadministered with efavirenz at 600 milligrams once
daily in healthy volunteers.
Soon GH, Shen P, Yong EL,et al.
Antimicrob Agents Chemother. 2010
Jul;54(7):2775-80.
Abstract
|
Pharmacokinetics of multiple-dose darunavir in combination
with low-dose ritonavir in
individuals with mild-to-moderate hepatic impairment.
Sekar V, Spinosa-Guzman S, De Paepe E, et sl
Clin Pharmacokinet.
2010 May 1;49(5):343-50.
Abstract
|
Pharmacokinetics of Darunavir 900mg and Ritonavir 100mg Once Daily when
Co-administered with Efavirenz 600mg Once Daily in Healthy Volunteers.
Soon GH, Shen P, Yong EL,et
al
Antimicrob Agents Chemother
2010 Apr 12
Abstract
|
Influence of darunavir coadministration on nevirapine pharmacokinetics in
HIV-infected patients:
a population approach.
Dailly E, Raffi F, Perré P, Martin J, et al
HIV Med. 2009 May 21
Abstract
|
Darunavir: pharmacokinetics and drug interactions.
Back D, Sekar V, Hoetelmans RM.
Antivir Ther. 2008;13(1):1-13.
Abstract
|
FULL-TEXT ARTICLE
Structural and thermodynamic basis for the binding of
TMC114, a next-generation human
immunodeficiency virus type 1 protease inhibitor.
King NM, Prabu-Jeyabalan M, Nalivaika EA, et al
J Virol. 2004 Nov;78(21):12012-21.
Paper |
|
| |
|
Factors Associated With Virological Failure in HIV-1-Infected
Patients Receiving Darunavir/Ritonavir Monotherapy.
Lambert-Niclot S, Flandre P,
Valantin MA,
et
al
J Infect Dis.
2011 Oct;204(8):1211-6
Abstract
Virological response to darunavir in patients infected with HIV
is linked to darunavi
resistance-associated mutations corrected by the count of
mutations with positive
impact and is not associated with pharmacological and combined
virological/
pharmacological parameters.
Dailly E, Rodallec A, Allavena C, Deslandes G, et al
Fundam Clin Pharmacol.
2011 May 5.
Abstract
Virological characterization of patients failing darunavir/ritonavir or
lopinavir/ritonavir treatment in
the ARTEMIS study:96-week analysis.
Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T,
et a|
Antivir Ther.
2011;16(1):99-108
Abstract
Effect of Baseline Viral Susceptibility on Response to
Darunavir/Ritonavir versus Control Protease Inhibitors
in Treatment-Experienced HIV Type 1-Infected Patients: POWER 1 and 2.
Pozniak A, Opravil M, Beatty G, et al
AIDS Res Hum Retroviruses. 2008 Oct 9.
Abstract
|
Darunavir Inhibitory Quotient Predicts the 48-Week Virological
Response to Darunavir -Based
Salvage Therapy in HIV-infected Protease Inhibitor- Experienced Adults
Moltó J, Santos JR, Pérez-Álvarez N, Cedeño S, et al
Antimicrob Agents Chemother. 2008 Aug 25
Abstract
|
|
| |
Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in
HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and
in Silico Binding Studies.
Midde NM, Gong Y, Cory TJ, et al
Pharm
Res. 2017 Jun 14
Abstract
Pharmacokinetic interactions between cobicistat-boosted elvitegravir and
darunavir in HIV-infected patient
Gutierrez-Valencia A,s.
Benmarzouk-Hidalgo OJ, Llaves S,
et
al;
J Antimicrob Chemother.
2016 Dec 20.
Abstract
FULL-TEXT ARTICLE
Interaction
between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism.
Belkhir L, Elens L, Zech F, et al
PLoS One. 2016 Oct
27;11(10):e0165631
Paper
Darunavir-based antiretroviral therapy may affect the efficacy of
ombitasvir/paritaprevir/ritonavir and dasabuvir in HCV/HIV-1 coinfected
patients.
Sollima S, D'Avolio A, Cattaneo D,
et al
Clin Infect Dis. 2016 May 3.
Abstract
Lack of pharmacokinetic interactions between Pitavastatin and
Efavirenz or Darunavir/Ritonavir.
Malvestutto CD, Ma Q, Morse GD, et al
J Acquir Immune Defic Syndr. 2014 Sep 8
Abstract
Early lipid changes with atazanavir/ritonavir or
darunavir/ritonavir.
Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, et al
HIV Med. 2014 Jan 12.
Abstract
Pharmacokinetic interaction between etravirine or darunavir/ritonavir
and artemether/lumefantrine in healthy volunteers: a two-panel, two-way,
two-period, randomized trial.
Kakuda T, Demasi R, van Delft Y, Mohammed P.
HIV Med.
2013 Feb 26.
Abstract
Pharmacokinetic Interactions Between the Hepatitis C Virus
Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1
Protease Inhibitors
Atazanavir, Darunavir, and Lopinavir.
Hulskotte EG, Feng HP, Xuan F, et al
Clin Infect Dis. 2012 Dec 14.
Abstract
Effect of Efavirenz, Nevirapine, Etravirine, Raltegravir
Administration on the Pharmacokinetics of Ritonavir-Boosted Darunavir
in a
Population of HIV-infected Patients.
Dailly E, Allavena C, Bouquié R,
et al
AIDS Res Hum Retroviruses. 2012 Nov 13.
Abstract |
Darunavir: A Critical Review of Its Properties, Use and
Drug Interactions.
Ruela Corrêa JC, D'Arcy DM, Dos Reis Serra CH, et al
Pharmacology.
2012 Jul
12;90(1-2):102
Abstract
Effect of Milk Thistle on the Pharmacokinetics of
Darunavir/Ritonavir in HIV-Infected Patients.
Moltó J, Valle M, Miranda C,
et al
Antimicrob Agents Chemother.
2012 Mar 19. [
Abstract |
Influence of SLCO1B1 Polymorphisms on the Drug-Drug Interaction
Between Darunavir/Ritonavir
and Pravastatin.
Aquilante CL, Kiser JJ, Anderson PL, et al
J Clin Pharmacol. 2011 Dec 14
Abstract |
Interactions Between Buprenorphine and the Protease Inhibitors
Darunavir-Ritonavir and
Fosamprenavir-Ritonavir
Gruber VA, Rainey PM, Moody DE,
et al
Clin Infect Dis.
2011 Nov 18.
Abstract
Steady-State Pharmacokinetic Interactions of Darunavir/Ritonavir With
Lipid-Lowering Agent Rosuvastatin.
Samineni D, Desai PB, Sallans L, Fichtenbaum CJ.
J Clin Pharmacol.
2011 Jun 28
Abstract
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir
in HIV-infected patients.
Moltó J, Valle M, Miranda C, et al
Antimicrob Agents Chemother.
2010 Nov
Abstract |
The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase
Inhibitor
S/GSK1349572 in Healthy Participants.
Song I, Min SS, Borland J, et al
J Clin Pharmacol.
2010 May 20.
Abstract |
Pharmacokinetics of Darunavir 900mg and Ritonavir 100mg Once Daily when
Co-administered with Efavirenz 600mg Once Daily in Healthy Volunteers.
Soon GH, Shen P, Yong EL,et
al
Antimicrob Agents Chemother
2010 Apr 12
Abstract
|
Pharmacokinetic Interaction between Indinavir and Darunavir
with Low-Dose Ritonavir in Healthy Volunteers.
Sekar V, Lefebvre E, De Marez T, et al
Intervirology.
2010 Mar 3;53(3):176-182.
Abstract |
Pharmacokinetic interaction between nevirapine and darunavir with
low-dose ritonavir in
HIV-1-infected patients.
Sekar V, Lefebvre E, Mariën K,
et al
Br J Clin Pharmacol.
2009 Jul;68(1):116-
Abstract
|
Pharmacological interactions with darunavir.
Moltó J, Valle M, Clotet B.
Enferm Infecc Microbiol Clin.
2008 Oct;26(Supl.10):43-50
Abstract
|
Pharmacokinetic interaction between TMC114/r and omeprazole or
ranitidine in HIV-negative
healthy volunteers.
Sekar VJ, Lefebvre E, De Paepe E, et al
Antimicrob Agents
Chemother. 2007 Jan 8;
Abstract
|
| |
Unique Flap Conformation in an HIV-1 Protease with High-Level
Darunavir Resistance.
Nakashima M, Ode H, Suzuki K,. et al
Front Microbiol. 2016
Feb 3;7:61
Abstract
Trends in Darunavir Resistance-Associated Mutations and
Phenotypic Resistance in Commercially Tested United States Clinical Samples
between 2006 and 2012*
Lathouwers E, Gupta S, Haddad M, et al
AIDS Res Hum Retroviruses.
2015 Feb 14.
Abstract
Low concordance and resistance mutation emergence in the HIV protease gene
among circulating and cell-associated viruses at
viral replication episodes during darunavir/ritonavir monotherapy.
Torres-Cornejo A, Benmarzouk-Hidalgo O, Gutierrez-Valencia A, et al.
HIV Med. 2014 Jun 9.
Abstract
A Contribution to the Drug Resistance Mechanism of Darunavir,
Amprenavir, Indinavir, and Saquinavir Complexes with HIV-1
Protease Due to
Flap Mutation I50V: A Systematic MM-PBSA and Thermodynamic Integration Study.
Leonis G,
Steinbrecher TB, Papadopoulos MG.
J Chem
Inf Model. 2013 Jul 8
Abstract
No evidence for evolution of genotypic resistance after
three years of treatment with darunavir/ritonavir,
with or without nucleoside analogues.
Pulido F, Arribas J, Hill A, Moecklinghoff C.
et al
AIDS Res Hum Retroviruses.
2012 Mar 2.
Abstract |
Emerging HIV-1 resistance to tipranavir and darunavir in
patients with virological failure to
first-generation protease inhibitors in Taiwan.
Hsieh SM, Chang SY, Hung CC, et al
Int J STD AIDS.
2011 Nov;22(11):617-20.
Abstract |
Selection of an M184V mutation in the cerebrospinal fluid of
a treatment-naive HIV-infected individual
starting darunavir-based therapy.
Cornelissen M, Back NK, Burger DM,
et al
Antivir Ther.
2011;16(6):931-5.
Abstract
The higher barrier of darunavir and tipranavir resistance
for HIV-1 protease.
Wang Y, Liu Z, Brunzelle JS,
et
aL
Biochem Biophys Res Commun.
2011 Sep 9;412(4):737-42
Abstract
Loss of Darunavir' s Protease Dimerization Inhibition
Activity is Associated with HIV-1 Acquisition
of Resistance to Darunavir
Koh Y, Aoki M, Danish ML, Aoki-Ogata H,
et al
J Virol. 2011
Aug 3
Abstract
FULL-TEXT ARTICLE
Prevalence and factors associated with darunavir resistance
mutations in multi-experienced HIV-1-infected patients
failing other protease inhibitors in a referral teaching
center in Brazil.
Vidal JE, Freitas AC, Song AT,
et al
Braz J Infect Dis.
2011 Jun;15(3):245-8
Paper
Virological response to darunavir in patients infected with
HIV is linked to darunavi
resistance-associated mutations corrected by the count of
mutations with positive
impact and is not associated with pharmacological and
combined virological/
pharmacological parameters.
Dailly E,
Rodallec A, Allavena C, Deslandes G, et al
Fundam Clin Pharmacol.
2011 May 5.
Abstract
Analysis of drug resistance during HIV RNA viraemia in the
MONET trial of darunavir/ritonavir
monotherapy.
Pulido F, Arribas JR, Hill A, et a
Antivir Ther.
2011;16(1):59-65.
Abstract
Comparative evaluation of seven resistance interpretation algorithms
and their derived
genotypic inhibitory quotients for the prediction of 48 week
virological response to
darunavir-based salvage regimens.
Gonzalez de Requena D, Bonora S, et al
J Antimicrob Chemother.
2010 Oct 29.
Abstract |
Impact of drug transporters on cellular resistance
towards saquinavir and darunavir.
König SK, Herzog M, Theile D, et al
J Antimicrob Chemother.
2010 Sep 3
Abstract |
In Vitro Selection of Highly Darunavir-Resistant and Replication
-Competent HIV-1
Variants Using a Mixture of Clinical HIV-1 Isolates Resistant To
Multiple Conventional
Protease Inhibitors.
Koh Y, Amano M, Towata T, et al
J Virol.
2010 Sep 1.
Abstract |
Resistance analyses in highly experienced patients failing
raltegravir, etravirine
and darunavir/ritonavir regimen.
Charpentier C, Roquebert B, Colin C, et al
AIDS. 2010 Aug 26
Abstract |
Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and
virtual phenotypic resistance patterns: an independent cohort analysis of
clinical
isolates highly resistant to all other protease inhibitors.
Talbot A, Grant P, Taylor J,
et al
Antimicrob Agents Chemother. 2010
Jun;54(6):2473-9
Abstract |
Drug Resistance Mutations in HIV-Infected Patients Failing Tipranavir
and
Darunavir in the Spanish Drug Resistance Database.
Poveda E, Anta L, Blanco JL, et al
Antimicrob Agents Chemother.
2010 May 17.
Abstract |
Predicting Tipranavir and Darunavir Resistance using Genotypic, Phenotypic
and Virtual Phenotypic Resistance Patterns: An Independent Cohort Analysis
of Clinical Isolates Highly Resistant to All Other Protease Inhibitors.
Talbot A, Grant P, Taylor J,
et al
Antimicrob Agents Chemother.
2010 Apr 5
Abstract |
Etravirine limits the emergence of darunavir and other protease
inhibitor resistance-associated
mutations in the DUET trials.
Peeters M, Vingerhoets J, Tambuyzer
L, et al
AIDS.
2010 Feb 12.
Abstract |
Insights into drug resistance of mutations D30N and I50V to HIV-1
protease inhibitor TMC-114:
Free energy calculation and molecular dynamic simulation.
Chen J, Zhang S, Liu X, Zhang Q.
J Mol Model.
2009 Jul 24.
Abstract |
Mutations associated with virological response to darunavir/ritonavir
in HIV-1-infected
protease inhibitor-experienced patients.
Descamps D, Lambert-Niclot S, Marcelin AG, et al
J Antimicrob Chemother.
2009 Jan 15.
Abstract
|
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1
protease with highly drug
resistant mutations D30N, I50V, and L90M.
Kovalevsky AY, Tie Y, Liu F, et al
J Med Chem. 2006 Feb
23;49(4):1379-87.
Abstract |
| |
|
High rate of virologic suppression with darunavir/ritonavir
plus optimized background therapy among highly antiretroviral-experienced
HIV-infected patients: results of a prospective cohort study in São Paulo,
Brazil.
Vidal JE, Song AT, Matos ML, et al
Braz J Infect Dis. 2013 Jan
Abstract
Efficacy and safety of switching double-boosted protease
inhibitors to boosted darunavir in HIV-infected patients with
virologic
suppression.
Curran A, Villar J, Burgos J, , et al
J Int AIDS Soc. 2012
Nov 11;15(6):18350.
Abstract
Predictors of long-term HIV RNA suppression on
darunavir/ritonavir monotherapy in the MONET trial.
Arribas J, Pulido F, Hill A, et al.
J Int AIDS Soc. 2012 Nov
11;15(6):18354.
Abstract
|
Final 192-week efficacy and safety of once-daily
darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected
treatment-naïve patients in the ARTEMIS trial.
Orkin C, Dejesus E, Khanlou H, et al;
HIV Med. 2012 Oct 23
Abstract
|
FULL-TEXT ARTICLE
Similar Evolution of Cellular HIV-1 DNA Level in Darunavir/Ritonavir
Monotherapy versus Triple Therapy in MONOI -
ANRS136 Trial over 96 Weeks.
Lambert-Niclot S, Flandre P, et al
PLoS One. 2012;7(7):e41390.
Paper
Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and
treatment-experienced adults with
HIV infection.
Robertson J, Feinberg J.
Expert Opin Pharmacother.
2012 May 17
Abstract
|
Week 96 Efficacy, Virology and Safety of Darunavir/r Versus
Lopinavir/r in Treatment-Experienced Patients
in
TITAN.
Bánhegyi D, Katlama C, da Cunha CA,
et al
Curr HIV Res. 2012
Feb 2.
Abstract
|
Efficacy and safety of once-daily ritonavir-boosted darunavir plus
abacavir/lamivudine for
treatment-naïve patients: A pilot study.
Nishijima T, Tsukada K, Teruya K,
et al
AIDS. 2012 Jan 10.
Abstract
|
Effect of Baseline Characteristics on the Efficacy and
Safety of Once-Daily Darunavir/ Ritonavir in HIV-1-Infected,
Treatment-Naïve ARTEMIS Patients at Week 96.
Fourie J, Flamm J, Rodriguez-French A,
HIV Clin Trials. 2011 Nov-Dec;12(6):313-22.
Abstract
Long-term efficacy of darunavir/ritonavir monotherapy in patients with
HIV-1 viral suppression: week 96
results from the MONOI ANRS 136 study.
Valantin MA, Lambert-Niclot S, Flandre P
et al
J Antimicrob Chemother.
2011 Dec 7
Abstract
Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients:
Observational Data
from the Randomized POTENT Trial.
Elgadi MM, Piliero PJ.
Drugs R D. 2011
Oct 18.
Abstract
Factors Associated With Virological Failure in
HIV-1-Infected Patients Receiving Darunavir/Ritonavir Monotherapy.
Lambert-Niclot S, Flandre P, Valantin MA,
et
al
J Infect Dis.
2011 Oct;204(8):1211-6.
Abstract
Efficacy of a Nucleoside-sparing Regimen of Darunavir/Ritonavir Plus
Raltegravir in
Treatment-Naïve HIV-1-infected Patients (ACTG A5262).
Taiwo B, Zheng L, Gallien S, et al
AIDS. 2011 Aug 19.
Abstract
Darunavir: an effective protease inhibitor for
HIV-infected patients.
Phung BC, Yeni P.
Expert Rev Anti Infect Ther.
2011 Jun;9(6):631-43
Abstract
96 week results from the MONET trial: a randomized comparison of
darunavir/ritonavir with
versus without nucleoside analogues, for patients with HIV RNA <50
copies/mL at baseline.
Clumeck N, Rieger A, Banhegyi D,
et al
J Antimicrob Chemother. 2011
Jun 7.
Abstract
ODIN: 48-week analysis of once- versus twice-daily
darunavir/ritonavir in treatment-experienced
HIV-1-infected patients.
Cahn P, Fourie J, Grinsztejn B, Hodder S, et al
AIDS. 2011 Feb 22
Abstract
Darunavir Outcomes Study: Comparative Effectiveness of Virologic
Suppression,
Regimen Durability, and Discontinuation Reasons for Three-Class
Experienced
Patients at 48 Weeks.
Willig JH, Aban I, Nevin CR, et al
AIDS Res Hum Retroviruses.
2010 Oct 21.
Abstract |
Efficacy, tolerability and risk factors for virological failure of
darunavir-based therapy for
treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.
Young J, Scherrer A, Günthard H, et al
HIV Med. 2010 Oct 18. doi: 10.111
Abstract |
Sex-Based Outcomes of Darunavir-Ritonavir Therapy: A Single-Group Trial.
Currier J, Averitt Bridge D, Hagins D, et al
Ann Intern Med. 2010 Sep
21;153(6):349-357
Abstract |
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1
viral
suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.
Katlama C, Valantin MA, Algarte-Genin M, et al
AIDS. 2010 Sep
24;24(15):2365-2374
Abstract |
Efficacy of darunavir/ritonavir maintenance monotherapy in patients
with HIV-1 viral
suppression: a randomized open-label, noninferiority trial, MONOI-ANRS
136.
Katlama C, Valantin MA, Algarte-Genin M, et al
AIDS. 2010 Aug 26
Abstract |
Efficacy, safety and pharmacokinetics of 900/100 mg of
darunavir/ritonavir once daily in
treatment-experienced patients.
Curran A, Gutirerrez M, Deig E,
et al
J Antimicrob Chemother. 2010 Aug 16
Abstract |
Suboptimal adherence to darunavir/ritonavir has minimal effect on
efficacy
compared with lopinavir/ritonavir in treatment-naive, HIV-infected
patients:
96 week ARTEMIS data.
Nelson M, Girard PM, Demasi R,
et al,
J
Antimicrob Chemother.
2010 May 24.
Abstract
|
Factors predictive of successful darunavir/ritonavir-based therapy in highly
antiretroviral-
experienced HIV-1-infected patients (the DARWEST study).
Delaugerre C, Buyck JF, Peytavin G, et al
J
Clin Virol. 2010 Mar;47(3):248-52.
Abstract |
Factors predictive of successful darunavir/ritonavir-based therapy in highly
antiretroviral-experienced HIV-1-infected patients (the DARWEST study).
Delaugerre C, Buyck JF, Peytavin G, et al
J Clin Virol. 2010 Jan 21
Abstract |
The MONET trial: darunavir/ritonavir with or without nucleoside
analogues, for patients
with HIV RNA below 50 copies/ml.
Arribas JR, Horban A, Gerstoft J, et al
AIDS.
AIDS. 2010 Jan 16;24(2):223-30.
Abstract |
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV
type-1 patients in the
POWER 1, 2 and 3 trials at week 96.
Arastéh K, Yeni P, Pozniak A, et al
Antivir Ther. 2009;14(6):859-64
Abstract |
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in
treatment-experienced
children and adolescents
Blanche S, Bologna R, Cahn P, et al
AIDS. 2009 Aug 30
Abstract
|
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive,
HIV-1-infected patients:
96-week analysis.
Mills AM, Nelson M, Jayaweera D, et al
AIDS. 2009 May 29.
Abstract
|
Early virologic suppression with three-class experienced patients: 24-week
effectiveness in the
darunavir outcomes study.
McKinnell JA, Lin HY, Nevin CN, et al
AIDS. 2009 May 29
Abstract |
Characterization of virologic failure patients on darunavir/ritonavir in
treatment-experienced patients.
De Meyer S, Lathouwers E, Dierynck I,
et al
AIDS. 2009 May 25.
Abstract
Darunavir: A Review of its Use in the Management of HIV Infection in
Adults.
McKeage K, Perry CM, Keam SJ.
Drugs.
2009;69(4):477-503
Abstract
|
Efficacy and Safety of Darunavir and Etravirine in an Antiretroviral
Multi-experienced Youth with
Vertically HIV-1 Infection.
Rosso R, Bernardini C, Bruzzone B,
et al
Eur J Med Res. 2009 Mar 17;14(3):136-8.
Abstract |
Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg
Once-Daily in
Treatment-Naïveand -Experienced Patients.
Boffito M, Miralles D, Hill A.
HIV Clin Trials.
2008 Jan 1;9(6):418-427
Abstract
|
Safety, Tolerability, and Efficacy of Darunavir (TMC114) with
Low-Dose Ritonavir in
Treatment-Experienced, Hepatitis B or C Co-infected Patients in
POWER 1 and 3.
Rachlis A, Clotet B, Baxter J, et al
HIV Clin Trials. 2007
Jul-Aug;8(4):213-20.
Abstract
Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in
Treatment-Experienced
Patients: 24-Week Results of POWER 3.
Molina JM, Cohen C, Katlama C, et al
J Acquir Immune Defic Syndr. 2007 Jul 5;
Abstract
Efficacy and safety of darunavir-ritonavir compared with that of
lopinavir-ritonavir at 48 weeks
in treatment-experienced, HIV-infected patients in TITAN: a randomised
controlled phase III trial.
Madruga JV, Berger D, McMurchie M, et al
Lancet. 2007 Jul 7;370(9581):49-58.
|
MC114/ritonavir substitution for protease inhibitor(s) in a
non-suppressive antiretroviral
regimen: a 14-day proof-of-principle trial.
Arasteh K, Clumeck N, Pozniak A, et al
AIDS. 2005 Jun 10;19(9):943-94
Abstract |
|
Darunavir Main Page
Main
New/Newsworthy
